Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for ...

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive ...

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions -- but there is always room for improvement. A new paper showcases the power of scalable protein ...

Researchers from the University of Eastern Finland, Aalto University and the University of Oulu have developed a new ...

More information: Lennart Hoengenaert et al, Transgene‐free genome editing in poplar, New Phytologist (2025). DOI: 10.1111/nph.20415 ...

More information: Trevor Weiss et al, Viral delivery of an RNA-guided genome editor for transgene-free germline editing in Arabidopsis, Nature Plants (2025). DOI: 10.1038/s41477-025-01989-9 ...

The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases.

Gene editing tools like CRISPR are revolutionizing ... Instead of integrating the CRISPR system into the plant's genome, the researchers used a technique called transient transformation.